P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2018

  • ID: 4590348
  • Drug Pipelines
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Asahi Kasei Pharma Corp
  • Axxam SpA
  • Evotec AG
  • Johnson & Johnson
  • Suven Life Sciences Ltd
  • MORE
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2018

Summary:

According to the recently published report 'P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2018'; P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 13 molecules.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.

The report 'P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2018' outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 4, 4 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Genetic Disorders and Gastrointestinal which include indications Epilepsy, Inflammation, Neuropathic Pain, Charcot-Marie-Tooth Disease Type I A, Multiple Sclerosis, Solid Tumor, Alzheimer's Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Depression, Duchenne Muscular Dystrophy, Inflammatory Bowel Disease, Major Depressive Disorder, Neuroinflammation and Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
  • The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Asahi Kasei Pharma Corp
  • Axxam SpA
  • Evotec AG
  • Johnson & Johnson
  • Suven Life Sciences Ltd
  • MORE
Introduction

Report Coverage

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec AG

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune Therapeutics Inc

Suven Life Sciences Ltd

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles

AFC-5128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKP-23494954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-010t - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-03s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-06v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-5446 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones

Featured News & Press Releases

Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma

Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma

Jan 25, 2012: Affectis Receives European Patent for AFC-5128 And Other P2X7 Antagonists

Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT

Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Affectis Pharmaceuticals AG, H2 2018

Pipeline by Asahi Kasei Pharma Corp, H2 2018

Pipeline by Axxam SpA, H2 2018

Pipeline by Biosceptre International Ltd, H2 2018

Pipeline by Evotec AG, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by Lead Discovery Center GmbH, H2 2018

Pipeline by MindImmune Therapeutics Inc, H2 2018

Pipeline by Suven Life Sciences Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Affectis Pharmaceuticals AG
  • Asahi Kasei Pharma Corp
  • Axxam SpA
  • Biosceptre International Ltd
  • Evotec AG
  • Johnson & Johnson
  • Lead Discovery Center GmbH
  • MindImmune Therapeutics Inc
  • Suven Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll